Evidence map›Paper›PMID 36157241›Full record

ArticleJournal of oncology2022

High Expression of EIF4G2 Mediated by the TUG1/Hsa-miR-26a-5p Axis Is Associated with Poor Prognosis and Immune Infiltration of Gastric Cancer.

Liu Fu, Zhe Wang, Fengxiang Jiang, Guohua Wei, Longe Sun, Chuanyong Guo, Jianye Wu, Jianhuan Zhu

Abstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liu FuDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0002-1424-6189
Zhe WangDepartment of Gastroenterology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.ORCID https://orcid.org/0000-0001-7909-0499
Fengxiang JiangDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0002-7071-4020
Guohua WeiDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0001-6836-6170
Longe SunDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0003-1132-3246
Chuanyong GuoDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0002-6527-4673
Jianye WuDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0003-2675-4241
Jianhuan ZhuDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai 200060, China.ORCID https://orcid.org/0000-0001-9645-3300

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) is involved in the occurrence and development of various tumors. However, the effect of EIF4G2 in gastric cancer (GC) has not been fully explored. The purpose of this study was to explore the function and mechanism of EIF4G2 in GC. Methods: The Tumor Immune Estimation Resource 2.0 database was used to analyze EIF4G2 expression in various cancers and the relationship between EIF4G2 expression and tumor-infiltrating immune cells. Gene Expression Profiling Interactive Analysis was utilized to assess the EIF4G2 expression level and its effect on survival in GC. UALCAN was conducted to analyze EIF4G2 expression in various subgroups of GC. The Kaplan-Meier plotter was employed for survival analysis. Receiver operator characteristic (ROC) curve analysis was applied to evaluate the diagnostic role of EIF4G2 in GC. LinkedOmics was used to identify the co-expressed genes and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. The Tumor-Immune System Interaction database was employed to analyze the correlation between EIF4G2 expression and tumor-infiltrating lymphocytes. The starBase web platform was used to predict the upstream microRNAs and long noncoding RNAs. Results: EIF4G2 expression was upregulated in GC tissues compared to normal controls. High expression of EIF4G2 indicated poor prognosis in GC. ROC analysis revealed that EIF4G2 had good diagnostic ability to distinguish GC from normal tissues. Immune infiltration analysis indicated that EIF4G2 expression may be involved in the modulation of tumor immune infiltration in GC. Finally, we determined that the Taurine Upregulated 1 (TUG1)/hsa-miR-26a-5p/EIF4G2 axis was the most likely regulatory pathway involved in GC development. Conclusions: EIF4G2 was upregulated in GC and elevated expression of EIF4G2 indicated unfavorable prognosis. Moreover, EIF4G2 expression may be involved in the regulation of tumor immune cell infiltration. The TUG1/hsa-miR-26a-5p axis is a likely upstream regulatory mechanism of EIF4G2 in GC. EIF4G2 may thus serve as a prognosis biomarker and present a new therapeutic target.

Identifiers

PMID36157241
PMCPMC9507702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.